BRIEF—Ten days after approval, Crysvita launches in USA

Following US Food and Drug Administration approval last month of its rare disease therapy Crysvita (burosumab), Ultragenyx Pharmaceutical and Japan’s Kyowa Hakko Kirin have announced the therapy is already available in US pharmacies.

Crysvita is the first drug for adults and children above the age of one with x-linked hypophosphatemia (XLH), a rare, inherited form of rickets.

Ultragenyx CEO Emil Kakkis said: “With this commercial launch of Crysvita, adults and children living with XLH now have access to the only treatment that targets the underlying cause of this debilitating disorder.”

The firms have also received conditional approval for the therapy in Europe.